Condition
Bipolar Disorder Clinical Trials
Studies of bipolar disorder, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 283Major Depressive Disorder, Bipolar I Disorder
Digital Phenotypes for Predicting Depression_Validation
This 12-month, single-site prospective observational study will prospectively monitor the recurrence of mood episodes while continuously collecting passive digital phenotypes in individuals with and without mood disorders.
- Conditions
- Major Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Mood Disorders
- Trial name
- NCT07880015
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Korea University Anam Hospital
Adolescent, Bipolar Depression
HD-tDCS for Adolescent Bipolar Depression Targeting S1
This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression.
- Conditions
- Adolescent, Bipolar Depression, tDCS, Primary Somatosensory Cortex
- Trial name
- NCT07246044
- Testing
- Active HD-tDCS, Antipsychotics, mood stabilizers, etc.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu Province Nanjing Brain Hospital
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
Anterior Bridge-Preserving Versus Conventional Early Apical Release in Bipolar Enucleation of the Prostate
Bipolar enucleation of the prostate is an effective operation for men with urinary obstruction caused by a benign enlarged prostate. Some men leak urine for a period after the operation.
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Obstruction, Stress Urinary Incontinence (SUI), Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
- Trial name
- ABPS-EAR-BIPO (NCT07893548)
- Testing
- Anterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR), Conventional Early Apical Release (EAR)
- Volunteers
- 230 people
- Sponsor
- Benha University
Bipolar Disorder Type I With Mania
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the…
- Trial name
- NCT06929273
- Testing
- KarXT, Lithium, Valproate
- Where
- 184 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
Bipolar-I Disorder With Mania or Mania With Mixed Features
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
- Trial name
- BALSAM-1 (NCT06951698)
- Testing
- KarXT
- Where
- 74 sites in United States, Argentina and 7 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Bipolar I Disorder
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
At present, the treatment of Bipolar I disorder (BD-I), especially its depressive episode (bipolar depression), is still limited, because there is no effective treatment for the associated cognitive impairment and perceived…
- Trial name
- NCT05977023
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Bipolar Disorder (BD), Quality of Life (QOL)
Evaluating the PolarUs App in People With Bipolar Disorder
Our team recently pilot tested a new mobile app, PolarUs, co-designed with people who live with bipolar disorder (BD), to support BD self-management and quality of life (QoL) measurement.
- Trial name
- NCT07890805
- Testing
- PolarUs Mobile App
- Where
- Canada
- Volunteers
- 504 people
- Sponsor
- University of British Columbia
Bipolar Disorder (BD)
Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression
Among psychiatric disorders, bipolar disorder stands out due to its alarmingly high suicide rates. This condition presents unique management challenges, especially during its depressive phase, which carries the highest risk of…
- Trial name
- B-HAPPI (NCT07664852)
- Testing
- Pramipexole
- Where
- Sweden
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Daniel Lindqvist
Bipolar Disorder Type I With Mania or Mania With Mixed Features
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features.
- Trial name
- NCT06951711
- Testing
- KarXT
- Where
- 85 sites in United States, China and 9 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Completed, with results posted
All 376Bipolar Disorder, Substance Use Disorders
Intervention for Comorbid Substance Use and Bipolar Disorders
This trial aims to evaluate the effectiveness of a novel intervention for patients with co-occurring bipolar and substance use disorders following a psychiatric hospitalization.
- Trial name
- ITAP (NCT04202393)
- Testing
- Integrated Treatment Adherence Program (ITAP), Safety Assessment and Follow-up Evaluation (SAFE)
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- Butler Hospital
Psychosis, Schizophrenia
Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
This clinical trial is a single center, single dose study of the acute effects of intranasal insulin on energy metabolism and cognitive function in patients with schizophrenia, schizoaffective and bipolar disorders, compared and…
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- NCT03943537
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Psychosis, Schizophrenia
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp).
- Conditions
- Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- CBTpro (NCT05127837)
- Testing
- CBTpro
- Where
- 13 sites in United States
- Volunteers
- 601 people
- Sponsor
- University of Washington
Bipolar Depression
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels
- Trial name
- NCT06229977
- Testing
- Palmitoylethanolamide (PEA), Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rodrigo Machado-Vieira, MD, PhD, MSc
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder.
- Conditions
- Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
- Trial name
- SERENITY II (NCT04276883)
- Testing
- Sublingual film containing Dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc